IL135469A0 - Methods for treating psychosis associated with glucocorticoid related dysfunction - Google Patents
Methods for treating psychosis associated with glucocorticoid related dysfunctionInfo
- Publication number
- IL135469A0 IL135469A0 IL13546998A IL13546998A IL135469A0 IL 135469 A0 IL135469 A0 IL 135469A0 IL 13546998 A IL13546998 A IL 13546998A IL 13546998 A IL13546998 A IL 13546998A IL 135469 A0 IL135469 A0 IL 135469A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- psychosis associated
- treating psychosis
- related dysfunction
- glucocorticoid
- Prior art date
Links
- 208000028017 Psychotic disease Diseases 0.000 title abstract 2
- 230000004064 dysfunction Effects 0.000 title 1
- 239000003862 glucocorticoid Substances 0.000 title 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 abstract 1
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 abstract 1
- 229960003248 mifepristone Drugs 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6097397P | 1997-10-06 | 1997-10-06 | |
| PCT/US1998/020906 WO1999017779A1 (en) | 1997-10-06 | 1998-10-05 | Methods for treating psychosis associated with glucocorticoid related dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL135469A0 true IL135469A0 (en) | 2001-05-20 |
Family
ID=22032889
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13546998A IL135469A0 (en) | 1997-10-06 | 1998-10-05 | Methods for treating psychosis associated with glucocorticoid related dysfunction |
| IL135469A IL135469A (en) | 1997-10-06 | 2000-04-04 | Use of glucocorticoid receptor antagonists in the preparation of drugs for the treatment of psychosis associated with glucocorticoid-related disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL135469A IL135469A (en) | 1997-10-06 | 2000-04-04 | Use of glucocorticoid receptor antagonists in the preparation of drugs for the treatment of psychosis associated with glucocorticoid-related disorders |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6150349A (enExample) |
| EP (1) | EP1023074B1 (enExample) |
| JP (3) | JP2001518509A (enExample) |
| KR (2) | KR100840957B1 (enExample) |
| CN (3) | CN1187053C (enExample) |
| AT (1) | ATE332696T1 (enExample) |
| AU (1) | AU747956B2 (enExample) |
| CA (1) | CA2302586C (enExample) |
| CY (1) | CY1106330T1 (enExample) |
| DE (1) | DE69835225T2 (enExample) |
| DK (1) | DK1023074T3 (enExample) |
| ES (1) | ES2268792T3 (enExample) |
| IL (2) | IL135469A0 (enExample) |
| NO (1) | NO327233B1 (enExample) |
| NZ (1) | NZ503250A (enExample) |
| PT (1) | PT1023074E (enExample) |
| WO (1) | WO1999017779A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0903146A1 (en) * | 1997-09-23 | 1999-03-24 | Applied Research Systems ARS Holdings N.V. | 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid |
| GB9915625D0 (en) * | 1999-07-02 | 1999-09-01 | Cortendo Ab | Method |
| US6620802B1 (en) * | 1999-11-23 | 2003-09-16 | Corcept Therapeutics, Inc. | Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist |
| AU1817902A (en) * | 2000-09-18 | 2002-03-26 | Applied Research Systems | Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) |
| NZ528147A (en) * | 2001-03-23 | 2005-06-24 | Corcept Therapeutics Inc | Methods for treating stress disorders using glucocorticoid receptor-specific antagonists |
| WO2002096433A1 (en) * | 2001-05-04 | 2002-12-05 | Corcept Therapeutics, Inc. | Methods for treating delirium using glucocorticoid receptor-specific antagonists |
| US7163934B2 (en) | 2001-05-04 | 2007-01-16 | Corcept Therapeutics, Inc. | Methods for treating delirium glucocorticoid receptor-specific antagonists |
| JP2004537563A (ja) | 2001-07-23 | 2004-12-16 | コーセプト セラピューティクス， インコーポレイテッド | 抗神経病薬誘導性体重増加を予防するための方法 |
| MXPA04001893A (es) * | 2001-08-31 | 2005-03-07 | Corcept Therapeutics Inc | Metodos para inhibir deterioro cognoscitivo en adultos con sindrome de down. |
| BR0213466A (pt) * | 2001-10-26 | 2004-11-09 | Akzo Nobel Nv | Uso de (11beta,17beta)-11-(1,3- benzodioxol-s-il)-17-hidróxi-17-(1-propinil) estra-4,9-dien-3-ona, preparação farmacêutica, e, método para o tratamento de um paciente sofrendo de distúrbio depressivo grave |
| JP2005513024A (ja) * | 2001-11-23 | 2005-05-12 | アクゾ・ノベル・エヌ・ベー | グルココルチコイド受容体アンタゴニストを用いる大うつ病性障害の治療 |
| US7326697B2 (en) * | 2002-04-29 | 2008-02-05 | Corcept Therapeutics, Inc. | Methods for increasing the therapeutic response to electroconvulsive therapy |
| CN1665515A (zh) * | 2002-07-02 | 2005-09-07 | 科塞普特治疗公司 | 治疗与干扰素α治疗相关的精神病的方法 |
| WO2004054587A1 (en) * | 2002-12-18 | 2004-07-01 | University Of Zurich | Treatment of neuro-psychiatric disorders |
| CA2514966A1 (en) * | 2003-02-04 | 2004-08-19 | Corcept Therapeutics, Inc. | Antiglucocorticoids for the treatment of postpartum psychosis |
| US8097606B2 (en) | 2003-07-23 | 2012-01-17 | Corcept Therapeutics, Inc. | Antiglucocorticoids for the treatment of catatonia |
| GB0400031D0 (en) | 2004-01-03 | 2004-02-04 | Univ Sheffield | Depression treatment |
| US20090156565A1 (en) * | 2004-12-03 | 2009-06-18 | The Children's Hospital Of Philadelphia | Composition and use thereof in enhancing a therapeutic effect of an antiepileptic drug |
| CN100588393C (zh) * | 2004-12-15 | 2010-02-10 | 上海三合生物技术有限公司 | 赛米司酮类用于治疗抑郁症的用途 |
| US20060229505A1 (en) * | 2005-04-08 | 2006-10-12 | Mundt James C | Method and system for facilitating respondent identification with experiential scaling anchors to improve self-evaluation of clinical treatment efficacy |
| WO2007131041A2 (en) * | 2006-05-02 | 2007-11-15 | Corcept Therapeutics, Inc. | The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2 |
| EP1987814A1 (en) * | 2007-04-30 | 2008-11-05 | Exelgyn | Mifepristone pharmaceutical compositions and their methods of preparation |
| RU2327448C1 (ru) | 2007-05-23 | 2008-06-27 | Виктор Иванович Рощин | Средство для лечения зависимости от этилового спирта и/или от наркотиков, фармацевтическая композиция, активный ингредиент фармацевтической композиции, способ лечения зависимости от этилового спирта и/или от наркотиков для лечения психосоматических и неврологических осложнений у алкоголиков и/или наркоманов |
| AU2008265898B2 (en) * | 2007-06-15 | 2013-11-28 | Research Triangle Institute | Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties |
| EP2576582B1 (en) * | 2010-05-26 | 2019-09-18 | Corcept Therapeutics, Inc. | Treatment of muscular dystrophy |
| WO2012106514A2 (en) | 2011-02-03 | 2012-08-09 | Pop Test Cortisol Llc | System and method for diagnosis and treatment |
| US10500216B2 (en) | 2011-11-18 | 2019-12-10 | Corcept Therapeutics, Inc. | Optimizing mifepristone absorption |
| US8986677B2 (en) * | 2012-07-30 | 2015-03-24 | Pop Test Cortisol Llc | Therapeutic compositions and methods |
| AU2016226451B2 (en) * | 2015-03-02 | 2019-12-19 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors |
| US9943526B2 (en) | 2015-04-21 | 2018-04-17 | Corcept Therapeutics, Inc. | Optimizing mifepristone levels for cushing's patients |
| EP3297728A4 (en) | 2015-05-18 | 2019-07-03 | Corcept Therapeutics Incorporated | METHOD FOR DIAGNOSIS AND ASSESSMENT OF THE TREATMENT OF THE CUSHING SYNDROME |
| CN109843183B (zh) * | 2016-10-21 | 2022-04-12 | 西铁城时计株式会社 | 检测装置 |
| KR20210153056A (ko) | 2019-03-18 | 2021-12-16 | 리네트 케이. 니만 | 인슐린 감수성 개선 방법 |
| US11903945B2 (en) | 2019-12-11 | 2024-02-20 | Corcept Therapeutics Incorporated | Methods of treating antipsychotic-induced weight gain with miricorilant |
| WO2023033900A1 (en) * | 2021-09-06 | 2023-03-09 | Slayback Pharma Llc | Pharmaceutical compositions of mifepristone |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4814333A (en) * | 1987-07-28 | 1989-03-21 | The Trustees Of Dartmouth College | Method for treatment of hypercortisolemic, depressed patients |
| US5348729A (en) * | 1988-11-30 | 1994-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Evaluative means for detecting inflammatory reactivity |
| FR2696934B1 (fr) * | 1992-10-20 | 1995-06-02 | Conservatoire Nal Arts Metiers | Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir. |
| IL118974A (en) * | 1995-08-17 | 2001-09-13 | Akzo Nobel Nv | History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them |
| FR2739029B1 (fr) * | 1995-09-21 | 1997-11-21 | Roussel Uclaf | Nouvelle application therapeutique des composes antimineralo-corticoides |
| ATE363908T1 (de) * | 1996-04-09 | 2007-06-15 | Univ Edinburgh | Verwendung von 7-alpha-substituierten steroiden zur behandlung von neuropsychiatrischen erkrankungen |
| FR2757400B1 (fr) * | 1996-12-19 | 1999-12-17 | Hoechst Marion Roussel Inc | Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs |
-
1998
- 1998-10-05 ES ES98950911T patent/ES2268792T3/es not_active Expired - Lifetime
- 1998-10-05 JP JP2000514650A patent/JP2001518509A/ja not_active Withdrawn
- 1998-10-05 DK DK98950911T patent/DK1023074T3/da active
- 1998-10-05 EP EP98950911A patent/EP1023074B1/en not_active Expired - Lifetime
- 1998-10-05 NZ NZ503250A patent/NZ503250A/en not_active IP Right Cessation
- 1998-10-05 CA CA002302586A patent/CA2302586C/en not_active Expired - Fee Related
- 1998-10-05 CN CNB988097923A patent/CN1187053C/zh not_active Expired - Fee Related
- 1998-10-05 KR KR1020077003769A patent/KR100840957B1/ko not_active Expired - Fee Related
- 1998-10-05 KR KR1020007003683A patent/KR100804558B1/ko not_active Expired - Fee Related
- 1998-10-05 CN CNA2006101003657A patent/CN1919199A/zh active Pending
- 1998-10-05 CN CNA200410039908XA patent/CN1528315A/zh active Pending
- 1998-10-05 DE DE69835225T patent/DE69835225T2/de not_active Expired - Lifetime
- 1998-10-05 AU AU96832/98A patent/AU747956B2/en not_active Ceased
- 1998-10-05 PT PT98950911T patent/PT1023074E/pt unknown
- 1998-10-05 WO PCT/US1998/020906 patent/WO1999017779A1/en not_active Ceased
- 1998-10-05 IL IL13546998A patent/IL135469A0/xx active IP Right Grant
- 1998-10-05 AT AT98950911T patent/ATE332696T1/de active
-
1999
- 1999-02-04 US US09/244,457 patent/US6150349A/en not_active Expired - Lifetime
-
2000
- 2000-04-04 IL IL135469A patent/IL135469A/en not_active IP Right Cessation
- 2000-04-05 NO NO20001744A patent/NO327233B1/no not_active IP Right Cessation
- 2000-08-15 US US09/639,377 patent/US6362173B1/en not_active Expired - Lifetime
-
2006
- 2006-10-05 CY CY20061101439T patent/CY1106330T1/el unknown
-
2008
- 2008-10-21 JP JP2008271442A patent/JP2009051858A/ja not_active Withdrawn
-
2009
- 2009-03-23 JP JP2009071039A patent/JP5180125B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001518509A (ja) | 2001-10-16 |
| KR20070032822A (ko) | 2007-03-22 |
| EP1023074B1 (en) | 2006-07-12 |
| CA2302586A1 (en) | 1999-04-15 |
| KR100804558B1 (ko) | 2008-02-20 |
| WO1999017779A1 (en) | 1999-04-15 |
| NO327233B1 (no) | 2009-05-18 |
| KR20010024431A (ko) | 2001-03-26 |
| PT1023074E (pt) | 2006-12-29 |
| JP2009132743A (ja) | 2009-06-18 |
| JP5180125B2 (ja) | 2013-04-10 |
| CY1106330T1 (el) | 2011-10-12 |
| NZ503250A (en) | 2001-09-28 |
| CA2302586C (en) | 2008-06-10 |
| DE69835225T2 (de) | 2007-07-05 |
| NO20001744D0 (no) | 2000-04-05 |
| ATE332696T1 (de) | 2006-08-15 |
| KR100840957B1 (ko) | 2008-06-24 |
| AU747956B2 (en) | 2002-05-30 |
| US6150349A (en) | 2000-11-21 |
| US6362173B1 (en) | 2002-03-26 |
| NO20001744L (no) | 2000-04-05 |
| JP2009051858A (ja) | 2009-03-12 |
| AU9683298A (en) | 1999-04-27 |
| CN1187053C (zh) | 2005-02-02 |
| CN1272788A (zh) | 2000-11-08 |
| EP1023074A1 (en) | 2000-08-02 |
| IL135469A (en) | 2007-03-08 |
| CN1919199A (zh) | 2007-02-28 |
| DE69835225D1 (de) | 2006-08-24 |
| DK1023074T3 (da) | 2006-11-06 |
| CN1528315A (zh) | 2004-09-15 |
| ES2268792T3 (es) | 2007-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL135469A0 (en) | Methods for treating psychosis associated with glucocorticoid related dysfunction | |
| IL154227A0 (en) | Chemokine receptor binding heterocyclic compounds | |
| EP1351670A4 (en) | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS WITH NMDA RECEPTOR ANTAGONISTS | |
| SG149693A1 (en) | Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use | |
| HUP0201184A2 (en) | Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction | |
| IL139344A0 (en) | Soluble t cell receptor | |
| IL139672A0 (en) | Glucocorticoid receptor antagonists for the treatment of dementia | |
| DK0946189T3 (da) | Anvendelse af aktivatorer af CNTF (ciliær neurotrofisk faktor) receptor til behandling af adipositas | |
| EP1109542A4 (en) | NITROSED AND NITROSYLATED ANTAGONISTS OF THE ALPHA ADRENERGIC RECEPTOR, COMPOSITIONS AND USES THEREOF | |
| IL159913A0 (en) | Methods for preventing antipsychotic-induced weight gain | |
| NO20003534L (no) | Progesteronreseptor-modulatorforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene | |
| AUPO755097A0 (en) | Receptor agonist and antagonist | |
| AP9901597A0 (en) | Vitronectin receptor antagonists. | |
| HUP0104780A3 (en) | Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors | |
| SG120119A1 (en) | Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors | |
| AP2003002924A0 (en) | 2,5-diarylpyrazines, 2,5 - diarylpyridines and 2,5 - diarylpyrimidines as CRF1 receptor modulators | |
| MY127120A (en) | A1 adenosine receptor antagonists | |
| HK1047050A1 (zh) | 治疗轻度智力机能缺陷的方法 | |
| IL144031A0 (en) | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents | |
| IL160649A0 (en) | Methods for inhibiting cognitive deterioration in adults with down syndrome | |
| IL158744A0 (en) | Methods for treating delirium using glucocorticoid receptor-specific antagonists | |
| HUP0302632A2 (hu) | Antigesztagének alkalmazása gyorsított endometriális érés gátlására meddőségi kezelés alatt | |
| DE60135773D1 (en) | Assays | |
| WO2001048483A3 (en) | Method for screening of appetite control agents | |
| AU2002219192A1 (en) | Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |